Extended Antibiotic Treatment Combined With Methenamine Hippurate Compared to Standard Care in Females With Chronic Urinary Tract Infection

What this Trial Is About

This research aims to evaluate treatments for chronic urinary tract infection UTI in females, a condition where symptoms occur every day without symptom-free breaks. Current treatments often involve low-dose antibiotics or methenamine hippurate but may not fully resolve symptoms. The trial investigates whether longer courses of higher-dose antibiotics combined with methenamine hippurate are more effective than standard care in reducing infection and symptoms. Participants will be randomly assigned to one of two groups. One group receives a higher-dose antibiotic cefalexin, nitrofurantoin, or trimethoprim combined with methenamine hippurate taken twice daily for 12 weeks. The other group receives a low-dose prophylactic antibiotic amoxicillin, cefalexin, nitrofurantoin, or trimethoprim or methenamine hippurate alone, also for 12 weeks. Treatments are selected by clinicians based on individual medical needs. During the 12-week treatment, participants visit the clinic every 4 weeks for assessments. They complete questionnaires and provide blood, urine, and perineal swab samples. Researchers measure changes in urinary white blood cell counts, symptom scores, quality of life, medication satisfaction, treatment adherence, urine cultures, and safety markers like vital signs and blood tests over the course of the study.

A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection